VASO Corp VASO
VASO Corp (VASO) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $89.1M at a 1.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.246 |
| Retained earnings / assets | -0.368 |
| EBIT / assets | -0.033 |
| Equity / liabilities | 0.499 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VASO | VASO Corp | 6/9 | 0.72 | 21.3 | +2.7% |
| CBLL | Ceribell, Inc. | 3/9 | 3.97 | — | +36.1% |
| BLFS | BIOLIFE SOLUTIONS INC | 6/9 | 10.32 | — | +28.9% |
| ELMD | Electromed, Inc. | 6/9 | 10.99 | 30.9 | +15.3% |
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
About VASO Corp
Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. It operates in three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed network infrastructure, such as routers, switches, and other core equipment; managed network transport; and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare, Inc. (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.
FAQ
Is VASO financially healthy?
VASO Corp's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does VASO pay a dividend?
No, VASO Corp does not currently pay a dividend.
How profitable is VASO?
In FY2025, VASO Corp had a net margin of 1.8% and a return on equity of 5.3%.
Is VASO overvalued or undervalued?
VASO Corp trades at about 30.0× trailing earnings — above its 10-year norm (10-year range 3.5×–18.0×, median 12.5×). Stocktoria reports the data, not buy/sell advice.
Is VASO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VASO Corp: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 21.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.